Cargando…

Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment

PURPOSE: This study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1) treatment. METHODS: Based on receiver operating characteristic curve (ROC) analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Da, Liangshan, Qu, Ziting, Zhang, Congjun, Shen, Yuanyuan, Huang, Wei, Zhang, Yiyin, Gu, Kangsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076857/
https://www.ncbi.nlm.nih.gov/pubmed/37035159
http://dx.doi.org/10.3389/fonc.2023.1144875
_version_ 1785020227965157376
author Da, Liangshan
Qu, Ziting
Zhang, Congjun
Shen, Yuanyuan
Huang, Wei
Zhang, Yiyin
Gu, Kangsheng
author_facet Da, Liangshan
Qu, Ziting
Zhang, Congjun
Shen, Yuanyuan
Huang, Wei
Zhang, Yiyin
Gu, Kangsheng
author_sort Da, Liangshan
collection PubMed
description PURPOSE: This study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1) treatment. METHODS: Based on receiver operating characteristic curve (ROC) analysis, Youden’s indexes were applied to determine the cut-off values for inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocye ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Wilcoxon test was conducted to evaluate the changes in above inflammatory markers. Kaplan-Meier method was utilized to estimate progression-free survival (PFS) and overall survival (OS), and the Log-rank test was used to compare the different survival between groups. Univariate and multivariate Cox regression analyses were performed to assess the prognostic value of inflammatory markers and clinical features. RESULTS: 162 advanced or metastatic ESCC patients receiving anti-PD-1 treatment were enrolled in this retrospective study. The cut-off values of NLR, dNLR, MLR, PLR, and SII were 4.748, 2.214, 0.309, 250.505, and 887.895, respectively. NLR, dNLR, PLR, and SII declined significantly among the partial response (PR) (P<0.001, P<0.001, P=0.036, P<0.001), objective response rate (ORR) (P<0.001, P<0.001, P=0.036, P<0.001), and disease control rate (DCR) (P<0.001, P<0.001, P=0.038, P<0.001) groups, respectively. Significant increases were found in NLR (P<0.001), dNLR (P<0.001), MLR (P=0.001), and SII (P=0.024) when anti-PD-1 treatment failed. Multivariate Cox regression analysis indicated that NLR (P<0.001, P=0.002), lymph node metastasis (P=0.013, P=0.001), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (P=0.008, P=0.002), and treatment lines (P=0.037, P=0.048) were significant prognostic indicators of PFS and OS. Additionally, SII (P=0.016) was also significantly related to OS in ESCC patients. The risk score model showed that low risk patients prolonged PFS and OS than those with middle or high risk (P<0.001, P<0.001). CONCLUSION: Inflammatory markers can reflect short-term outcomes of anti-PD-1 treatment for ESCC patients. NLR, lymph node metastases, ECOG PS, and treatment lines are significant prognostic indicators for PFS and OS. And the risk score model constructed based on the above factors has favourable prognostic predictive value.
format Online
Article
Text
id pubmed-10076857
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100768572023-04-07 Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment Da, Liangshan Qu, Ziting Zhang, Congjun Shen, Yuanyuan Huang, Wei Zhang, Yiyin Gu, Kangsheng Front Oncol Oncology PURPOSE: This study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1) treatment. METHODS: Based on receiver operating characteristic curve (ROC) analysis, Youden’s indexes were applied to determine the cut-off values for inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocye ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Wilcoxon test was conducted to evaluate the changes in above inflammatory markers. Kaplan-Meier method was utilized to estimate progression-free survival (PFS) and overall survival (OS), and the Log-rank test was used to compare the different survival between groups. Univariate and multivariate Cox regression analyses were performed to assess the prognostic value of inflammatory markers and clinical features. RESULTS: 162 advanced or metastatic ESCC patients receiving anti-PD-1 treatment were enrolled in this retrospective study. The cut-off values of NLR, dNLR, MLR, PLR, and SII were 4.748, 2.214, 0.309, 250.505, and 887.895, respectively. NLR, dNLR, PLR, and SII declined significantly among the partial response (PR) (P<0.001, P<0.001, P=0.036, P<0.001), objective response rate (ORR) (P<0.001, P<0.001, P=0.036, P<0.001), and disease control rate (DCR) (P<0.001, P<0.001, P=0.038, P<0.001) groups, respectively. Significant increases were found in NLR (P<0.001), dNLR (P<0.001), MLR (P=0.001), and SII (P=0.024) when anti-PD-1 treatment failed. Multivariate Cox regression analysis indicated that NLR (P<0.001, P=0.002), lymph node metastasis (P=0.013, P=0.001), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (P=0.008, P=0.002), and treatment lines (P=0.037, P=0.048) were significant prognostic indicators of PFS and OS. Additionally, SII (P=0.016) was also significantly related to OS in ESCC patients. The risk score model showed that low risk patients prolonged PFS and OS than those with middle or high risk (P<0.001, P<0.001). CONCLUSION: Inflammatory markers can reflect short-term outcomes of anti-PD-1 treatment for ESCC patients. NLR, lymph node metastases, ECOG PS, and treatment lines are significant prognostic indicators for PFS and OS. And the risk score model constructed based on the above factors has favourable prognostic predictive value. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076857/ /pubmed/37035159 http://dx.doi.org/10.3389/fonc.2023.1144875 Text en Copyright © 2023 Da, Qu, Zhang, Shen, Huang, Zhang and Gu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Da, Liangshan
Qu, Ziting
Zhang, Congjun
Shen, Yuanyuan
Huang, Wei
Zhang, Yiyin
Gu, Kangsheng
Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
title Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
title_full Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
title_fullStr Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
title_full_unstemmed Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
title_short Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
title_sort prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076857/
https://www.ncbi.nlm.nih.gov/pubmed/37035159
http://dx.doi.org/10.3389/fonc.2023.1144875
work_keys_str_mv AT daliangshan prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment
AT quziting prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment
AT zhangcongjun prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment
AT shenyuanyuan prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment
AT huangwei prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment
AT zhangyiyin prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment
AT gukangsheng prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment